Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Gains from Investment Securities (2016 - 2021)

Phio Pharmaceuticals' Gains from Investment Securities history spans 10 years, with the latest figure at $1000.0 for Q4 2021.

  • For Q4 2021, Gains from Investment Securities changed N/A year-over-year to $1000.0; the TTM value through Dec 2021 reached $3000.0, up 50.0%, while the annual FY2024 figure was $5000.0, 80.77% down from the prior year.
  • Gains from Investment Securities reached $1000.0 in Q4 2021 per PHIO's latest filing, up from $43.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $157514.0 in Q3 2018 to a low of $43.0 in Q3 2021.
  • Average Gains from Investment Securities over 5 years is $50729.5, with a median of $33038.0 recorded in 2017.
  • Peak YoY movement for Gains from Investment Securities: soared 376.77% in 2018, then crashed 98.66% in 2020.
  • A 5-year view of Gains from Investment Securities shows it stood at $50180.0 in 2017, then surged by 213.9% to $157514.0 in 2018, then plummeted by 90.48% to $15000.0 in 2019, then tumbled by 86.67% to $2000.0 in 2020, then crashed by 50.0% to $1000.0 in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Gains from Investment Securities are $1000.0 (Q4 2021), $43.0 (Q3 2021), and $2499.0 (Q2 2021).